Advanced search for publications
Enter your keywords
Opioids – MO opportunities
Overview At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and […]
Sodium Valproate – MO opportunities
Overview At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and […]
Antidepressants – MO opportunities
Overview At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and […]
Formulary assessment – levodopa inhalation powder (Inbrija)
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies. The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The […]
Drugs for Dementia
This report looks at prescribing trends in primary care for Drugs for Dementia at SICBL and ICB level with particular focus on low strength antipsychotics. Prescribing data is weighted with QOF registers. If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net Frequency Quarterly Data Period October 2022 to […]
Pain Management
This report looks at prescribing trends in primary care in relation to Pain Management at ICB and Sub Integrated Board location (SICBl) with particular focus on Opioid and Non-opioid analgesics, Neuropathic pain, Antimigraine drugs and Osteoarthritis. If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net Frequency Bi-annually Data […]
Budget impact of prescribing haloperidol 500 microgram tablets
The purpose of this bulletin is to highlight the inflated NHS price of haloperidol 500 microgram tablets and to demonstrate the potential savings of using alternative presentations to provide the same dose. It shows the current annual primary care spend on haloperidol 500 microgram tablets and potential annual opportunity within RDTC stakeholder ICBs.
Formulary assessment – Pregabalin prolonged-release tablets
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies. The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The […]
NHS Medicines Optimisation Opportunities Dashboard
At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and deliver […]
Safer Medication Use – Propranolol in the treatment of anxiety
Propranolol is increasingly used for the treatment of anxiety. However, several recent critical incidents have raised concerns that there may still be a lack of awareness amongst prescribers over the risks associated with propranolol in overdose. This report aims to raise awareness of the potential toxicity of propranolol in overdose and highlight a specific group […]